TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06193057

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total ankle arthroplasty
Description: Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total ankle arthroplasty
Description: Patients who underwent ankle prosthesis implantation procedure with an anterior approach were involved in a longitudinal skin incision of about 12-15cm anterior to the tibio-tarsal joint in supine position. Once the deep layers were reached, passing through the anterior tibial tendon and extensor hallucis longus tendon sheath, the tibio-tarsal joint was then exposed. The operator proceeds to astragalic and tibial resections, once the appropriate size of implants was selected, the final components were implanted. In both groups, the basic prosthetic design approach will be 'three-component,' that is, with congruent mobile meniscus interposed between the tibial and astragalic components. At the end of the procedure, orthopedic walker boot was placed for 3 weeks, and progressive weight allowed.
Study: NCT05936346

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salvia haenkei 175mg
Description: The product appears as a soft gel containing the dry extract of Salvia haenkei

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salvia haenkei 350mg
Description: The product appears as a soft gel containing the dry extract of Salvia haenkei
Study: NCT04592978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain-Alcohol Personalized Feeback Intervention
Description: The intervention will be designed to enhance knowledge regarding adverse pain-alcohol-opioid interrelations as well as increase motivation and intention to reduce hazardous drinking and positive attitudes and intentions regarding concurrent use of alcohol and prescription opioid medications.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Personalized Feedback Intervention
Description: The control intervention will incorporate personalized feedback relevant to exercise and nutrition but not address drinking reduction or pain-alcohol-opioid interrelations.
Study: NCT05727930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity, task-specific (i.e., walking) interventions
Description: Up to 30 1-hr sessions of training focused on walking trying to achieve higher cardiovascular intensities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity, non-specific physical therapy interventions
Description: Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve higher cardiovascular intensities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity, task-specific physical therapy interventions
Description: Up to 30 1-hr sessions of training focused on walking trying to achieve lower cardiovascular intensities

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity, non-specific physical therapy interventions
Description: Up to 30 1-hr sessions of training focused on varied physical interventions trying to achieve lower cardiovascular intensities
Study: NCT05655156

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoPure XT
Description: Indication: reconstruction of knee ligaments to restore knee function and stability~The following device sizes are available for use in this indication:~* Size 5~  - Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 6~  - Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 8~  * Primary ACL reconstruction where autograft tissue is not suitable~ * Revision ACL reconstruction~ * Multi-ligament reconstruction (recommended for extra-articular ligament reconstruction)~* Size 10~  * Multi-ligament reconstruction (recommended for posterior cruciate ligament (PCL) reconstruction)
Study: NCT05853835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPX-TI641
Description: LAPIX Therapeutics Inc (LAPIX) has developed LPX-TI641, a small molecule for immune tolerance restoration/induction that is an orally bioavailable Tim family agonist (Tim-3 and Tim-4).
Study: NCT05433584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihyperglycemic medication
Description: As prescribed
Study: NCT05363683

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Squat Biofeedback
Description: The intervention group will complete bilateral squats with each limb on a separate portable force plate. They will receive real-time visual feedback on a 32-inch screen during all squats. Biofeedback conditions will be progressed from simplest (ground reaction force only) to most complex (ground reaction force plus center of pressure). This intervention will be included in additional to standard care post-operative physical therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard care post-operative physical therapy
Study: NCT04340180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) gadolinium Breast MRI
Description: Standard of Care (SOC) gadolinium Breast MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
Description: reduced 1/4 dose gadolinium Breast MRI with Artificial Intelligence (AI) to aid in evaluation.
Study: NCT06437769

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reiki
Description: effect of reiki application to women who have been hospitalized by ceserean during the hospitlalization process on anxiety depression comfort and breastfeesing
Study: NCT05978804

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: Computerized Cognitive training (BrainHQ or Constant Therapy)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS (tDCS) on DLPFC
Description: Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS (tDCS) on DLPFC
Description: Device: Active tDCS on DLPFC Stimulation will be delivered by a constant current stimulator (Mind STIM). The electrical current will be administered to a pre-specified region of the brain (DLPFC). The stimulation will be delivered at an intensity of 2 milliamperes (mA) (estimated current density 0.04 mA/cm2; estimated total charge 0.048 Coulombs/cm2) in a ramp-like fashion for a maximum of 20 minutes.
Study: NCT06394830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNX001
Description: Intravesical administration of VNX001
Study: NCT06064097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest Radiography
Description: Undergo chest x-ray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluciclovine F18
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study: NCT05467111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Exercise
Description: Patients will perform an acute bout of exercise (different types of exercise for each cycle of anthracyclines, as aerobic exercise, strength training or combined training) 24-48 hours prior to each cycle of anthracyclines.
Study: NCT06064097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06237374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Vaccine Education Training & Patient-facing Chatbot Tool
Description: The first part of the intervention is a digital training provided to CHWs, which includes videos and job aids on vaccine education to support patient communication. The second part of the intervention is a patient-facing chatbot designed to provide key information about routine immunization that CHWs can share with their patients through the social media and messenger application, WhatsApp.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Training
Description: All CHWs in the study will receive the standard CHW training that is provided on an ongoing basis by Lwala Community Health Alliance.
Study: NCT06064097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Receive radiation therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo dental x-ray
Study: NCT05560763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowTriever2 Catheter
Description: The FlowTriever2 Catheter is utilized for the treatment of Pulmonary Embolism
Study: NCT04755283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abelacimab
Description: Abelacimab provided as liquid in vial (150 mg/mL)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban 15 mg and 20 mg provided as commercially available film-coated tablets
Study: NCT06339008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3650150
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3650150
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for INCS
Description: Administered as intranasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard therapy for INCS
Description: Administered as intranasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard therapy for INCS
Description: Administered as intranasal spray
Study: NCT06191042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: si-544
Description: Subcutaneous injection in the abdomen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection in the abdomen
Study: NCT04466488

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choice Architecture
Description: 1. Providers will receive general training on TPT benefits, indications, and contra-indications.~2. Providers will be provided with updated ART and TPT prescribing approach, including an ink stamp or pre-printed sticker for quick entry of the ART prescription along with TPT and cotrimoxazole.~3. The pharmacy or clinician (if the clinician dispenses) will dispense ART, cotrimoxazole, and TPT as prescribed
Study: NCT05614765

Intervention type: DRUG
Intervention: Statin+Ezetimibe compound
Description: Crezet Tablet, Litorvazet Tablet
Study: NCT06546930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DREAM intervention
Description: Virtual Peer Groups (VPGs)~Participants will have multiple opportunities to attend a VPG on a specific topic during their 12-month participation period. The VPG topics will include the following:~* Diabetes technology - basics or advanced use (audience-dependent)~* Family relationships and diabetes~* Diabetes in real life - school, work, social gatherings, travel~* Wellbeing and support when living with diabetes~* Working with your diabetes care team - who to call for what~* Eating and activity - what's different with T1D?~In-Person Events will be held quarterly to facilitate participant interaction and community-building. These gatherings will feature ice-breaker activities, refreshments, and hands-on learning opportunities, including the chance to interact with specific diabetes devices and engage with healthcare professionals and representatives from diabetes technology companies.
Study: NCT04892940

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) technique
Description: The PICO G2 4k helmet from the Chinese manufacturer Pico which is an autonomous virtual reality helmet will be used.~The sessions proposed last 20 minutes with a child pain protocol. The teenager will be able to choose his universe (forest, beach, mountain, aquatic, space), the voice that accompanies him (man, woman, none), the sound environment of music therapy (6 to choose from).~Each patient in the experimental group benefits from a virtual reality program including two daily sessions during their stay in the continuing care unit from the first post-operative day until the third post-operative day. Each session is proposed by a nurse anesthetist from the pain team and trained in the proper use of the equipment.This virtual reality program will be added to the standard analgesic protocol for the experimental group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic protocol
Description: Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Analgesic protocol
Description: Patients randomized in the control group receive the usual analgesic protocol of the department postoperatively.
Study: NCT06150820

Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: No investigational drug will be administered to participants in this study.
Study: NCT06524947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quadrivalent recombinant norovirus vaccine (Pichia pastoris)
Description: Subjects were given three doses of quadrivalent recombinant norovirus vaccine (Pichia pastoris) at a 30-day interval.~Main ingredients: recombinant ReNoV GI.1-VP1 protein, recombinant ReNoV GII.3-VP1 protein, recombinant ReNoVGII.4-VP1 protein, recombinant ReNoV GII.17-VP1 protein, aluminum hydroxide adjuvant, histidine, sodium chloride, tween 80, disodium phosphate, disodium hydrogen phosphate
Study: NCT06237374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Training
Description: All CHWs in the study will receive the standard CHW training that is provided on an ongoing basis by Lwala Community Health Alliance.
Study: NCT06391229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Support
Description: Caregivers will receive up to four, 60- to 90-minute sessions focused on teaching two parenting skills - attentive listening and comforting. Attentive listening involves providing accurate and timely responses to show interest and keep the child engaged until they are ready to end the conversation. Comforting involves using the same attentive listening skills when the child is upset or distressed. Effective mastery of the listening and comforting skills also requires caregivers to withhold any non-listening or non-comforting responses (e.g., interruptions, criticisms).~The program is individually tailored such that caregivers with stronger skills could complete the program in less time (i.e., fewer sessions). Service providers educate caregivers about the skills, then engage in an iterative process of modeling the skills, engaging the caregivers in behavioral practice, and providing tailored, supportive feedback to help caregivers gain mastery.
Study: NCT06233123

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the Medisafe android application (https://www.medisafe.com).
Description: software for Android mobile phones that can remind the patient of his treatment on time
Study: NCT05585307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bavtavirine
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (Substudy 01)
Description: Antiretroviral therapy, administered orally~Non-NNRTIs, examples: ABC/DTG/3TC; DTG plus (TAF or TDF) plus (FTC or 3TC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-1720
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (Substudy 02)
Description: Antiretroviral therapy, administered orally~Example INSTIs: DTG/ABC/3TC or DTG/3TC
Study: NCT05611138

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Participants will be instructed to dissolve the protein powder in liquids (such as water) or on their food (e.g., yoghurt, oat porridge). A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge, where they will receive the daily protein portion as breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Participants will be instructed to dissolve the protein powder in liquids (such as water) or on their food (e.g., yoghurt, oat porridge). A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge, where they will receive the daily protein portion as breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Participants will be instructed to dissolve the protein powder in liquids (such as water) or on their food (e.g., yoghurt, oat porridge). A subset of the participants (max. 15 per arm) for visits 2 and 6 will be invited to participate in a postprandial challenge, where they will receive the daily protein portion as breakfast.
Study: NCT05952830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESWT group
Description: subjects in ESWT-group receiving one session shock wave therapy given 6,000 impulses at 0.06-0.07 mJ/mm2 (1.2-1.4 bar) at 18 Hz on biceps brachii (17). Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESWT group
Description: subjects in ESWT-group receiving one session shock wave therapy given 6,000 impulses at 0.06-0.07 mJ/mm2 (1.2-1.4 bar) at 18 Hz on biceps brachii (17). Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DN group
Description: Subjects in DN-group receiving dry needling using disposable stain less steel sterilized needles, 0.25×0.30. DN perform with patients in supine position, arm away from the trunk, and forearm in supination. The fast-in and fast-out cone shape technique adopt and each muscle needled for one minute